Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $457.24 million. The enterprise value is $559.19 million.
| Market Cap | 457.24M |
| Enterprise Value | 559.19M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 67.34 million shares outstanding. The number of shares has increased by 8.92% in one year.
| Current Share Class | 55.38M |
| Shares Outstanding | 67.34M |
| Shares Change (YoY) | +8.92% |
| Shares Change (QoQ) | +4.25% |
| Owned by Insiders (%) | 14.96% |
| Owned by Institutions (%) | 53.55% |
| Float | 49.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.45 |
| Forward PS | 5.31 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.96.
| Current Ratio | 4.57 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.94% and return on invested capital (ROIC) is -19.90%.
| Return on Equity (ROE) | -59.94% |
| Return on Assets (ROA) | -16.72% |
| Return on Invested Capital (ROIC) | -19.90% |
| Return on Capital Employed (ROCE) | -32.38% |
| Weighted Average Cost of Capital (WACC) | 7.48% |
| Revenue Per Employee | $273,033 |
| Profits Per Employee | -$599,594 |
| Employee Count | 485 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -594,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.79% in the last 52 weeks. The beta is 1.79, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.79 |
| 52-Week Price Change | -48.79% |
| 50-Day Moving Average | 8.57 |
| 200-Day Moving Average | 8.56 |
| Relative Strength Index (RSI) | 34.34 |
| Average Volume (20 Days) | 1,014,272 |
Short Selling Information
The latest short interest is 5.32 million, so 7.90% of the outstanding shares have been sold short.
| Short Interest | 5.32M |
| Short Previous Month | 5.16M |
| Short % of Shares Out | 7.90% |
| Short % of Float | 10.66% |
| Short Ratio (days to cover) | 5.79 |
Income Statement
In the last 12 months, DNA had revenue of $132.42 million and -$290.80 million in losses. Loss per share was -$4.96.
| Revenue | 132.42M |
| Gross Profit | 90.10M |
| Operating Income | -297.06M |
| Pretax Income | -310.23M |
| Net Income | -290.80M |
| EBITDA | -261.73M |
| EBIT | -297.06M |
| Loss Per Share | -$4.96 |
Balance Sheet
The company has $302.16 million in cash and $404.11 million in debt, with a net cash position of -$101.95 million or -$1.51 per share.
| Cash & Cash Equivalents | 302.16M |
| Total Debt | 404.11M |
| Net Cash | -101.95M |
| Net Cash Per Share | -$1.51 |
| Equity (Book Value) | 420.28M |
| Book Value Per Share | 6.60 |
| Working Capital | 259.80M |
Cash Flow
In the last 12 months, operating cash flow was -$170.24 million and capital expenditures -$4.56 million, giving a free cash flow of -$174.80 million.
| Operating Cash Flow | -170.24M |
| Capital Expenditures | -4.56M |
| Depreciation & Amortization | 35.33M |
| Net Borrowing | -68,000 |
| Free Cash Flow | -174.80M |
| FCF Per Share | -$2.60 |
Margins
Gross margin is 68.04%, with operating and profit margins of -224.33% and -219.60%.
| Gross Margin | 68.04% |
| Operating Margin | -224.33% |
| Pretax Margin | -234.28% |
| Profit Margin | -219.60% |
| EBITDA Margin | -197.65% |
| EBIT Margin | -224.33% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.92% |
| Shareholder Yield | -8.92% |
| Earnings Yield | -63.60% |
| FCF Yield | -38.23% |
Analyst Forecast
The average price target for DNA is $7.00, which is 3.09% higher than the current price. The consensus rating is "Sell".
| Price Target | $7.00 |
| Price Target Difference | 3.09% |
| Analyst Consensus | Sell |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 20.32% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -8.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.82 |
| Piotroski F-Score | 1 |